Gabriel Helmlinger
Gabriel Helmlinger
Executive Director, AstraZeneca Pharmaceuticals
Подтвержден адрес электронной почты в домене astrazeneca.com
Название
Процитировано
Процитировано
Год
Interstitial pH and pO 2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation
G Helmlinger, F Yuan, M Dellian, RK Jain
Nature medicine 3 (2), 177-182, 1997
16651997
Solid stress inhibits the growth of multicellular tumor spheroids
G Helmlinger, PA Netti, HC Lichtenbeld, RJ Melder, RK Jain
Nature biotechnology 15 (8), 778-783, 1997
7021997
Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism
G Helmlinger, A Sckell, M Dellian, NS Forbes, RK Jain
Clinical Cancer Research 8 (4), 1284-1291, 2002
4182002
Effects of pulsatile flow on cultured vascular endothelial cell morphology
G Helmlinger, RV Geiger, S Schreck, RM Nerem
3501991
Formation of endothelial cell networks
G Helmlinger, M Endo, N Ferrara, L Hlatky, RK Jain
Nature 405 (6783), 139-141, 2000
1842000
Calcium responses of endothelial cell monolayers subjected to pulsatile and steady laminar flow differ
G Helmlinger, BC Berk, RM Nerem
American Journal of Physiology-Cell Physiology 269 (2), C367-C375, 1995
1731995
Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis
KM Hallow, G Helmlinger, PJ Greasley, JJV McMurray, DW Boulton
Diabetes, Obesity and Metabolism 20 (3), 479-487, 2018
1242018
Pulsatile and steady flow-induced calcium oscillations in single cultured endothelial cells
G Helmlinger, BC Berk, RM Nerem
Journal of vascular research 33 (5), 360-369, 1996
981996
Fluorescence ratio imaging of interstitial pH in solid tumours: effect of glucose on spatial and temporal gradients
M Dellian, G Helmlinger, F Yuan, RK Jain
British journal of cancer 74 (8), 1206-1215, 1996
871996
Preclinical cardiac safety assessment of pharmaceutical compounds using an integrated systems-based computer model of the heart
D Bottino, RC Penland, A Stamps, M Traebert, B Dumotier, A Georgieva, ...
Progress in biophysics and molecular biology 90 (1-3), 414-443, 2006
672006
A mechanistic tumor penetration model to guide antibody drug conjugate design
C Vasalou, G Helmlinger, B Gomes
PloS one 10 (3), e0118977, 2015
662015
Primary proximal tubule hyperreabsorption and impaired tubular transport counterregulation determine glomerular hyperfiltration in diabetes: a modeling analysis
KM Hallow, Y Gebremichael, G Helmlinger, V Vallon
American Journal of Physiology-Renal Physiology 312 (5), F819-F835, 2017
412017
Understanding pharmacokinetics using realistic computational models of fluid dynamics: biosimulation of drug distribution within the CSF space for intrathecal drugs
A Kuttler, T Dimke, S Kern, G Helmlinger, D Stanski, LA Finelli
Journal of pharmacokinetics and pharmacodynamics 37 (6), 629-644, 2010
362010
An integrated approach for inference and mechanistic modeling for advancing drug development
SV Aksenov, B Church, A Dhiman, A Georgieva, R Sarangapani, ...
FEBS letters 579 (8), 1878-1883, 2005
332005
Radiation and PD-(L) 1 treatment combinations: immune response and dose optimization via a predictive systems model
Y Kosinsky, SJ Dovedi, K Peskov, V Voronova, L Chu, H Tomkinson, ...
Journal for immunotherapy of cancer 6 (1), 17, 2018
242018
Chap. 6 Shear stress effects on the morphology and cytomatrix of cultured vascular endothelial cells
PR Girard
Physical forces and the mammalian cell, 193-222, 1993
221993
Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data
KM Hallow, PJ Greasley, G Helmlinger, L Chu, HJ Heerspink, DW Boulton
American Journal of Physiology-Renal Physiology 315 (5), F1295-F1306, 2018
202018
Implications of dynamic occupancy, binding kinetics, and channel gating kinetics for hERG blocker safety assessment and mitigation
R A Pearlstein, K Andrew MacCannell, G Erdemli, S Yeola, G Helmlinger, ...
Current Topics in Medicinal Chemistry 16 (16), 1792-1818, 2016
132016
Requirements for multi-level systems pharmacology models to reach end-usage: the case of type 2 diabetes
E Nyman, YJW Rozendaal, G Helmlinger, B Hamrén, MC Kjellsson, ...
Interface focus 6 (2), 20150075, 2016
132016
Multiscale mathematical model of drug-induced proximal tubule injury: linking urinary biomarkers to epithelial cell injury and renal dysfunction
Y Gebremichael, J Lu, H Shankaran, G Helmlinger, J Mettetal, KM Hallow
Toxicological Sciences 162 (1), 200-211, 2018
112018
В данный момент система не может выполнить эту операцию. Повторите попытку позднее.
Статьи 1–20